Alkermes
evaluating multiple potential dosing options to provide flexibility and support clinical utility | Alkermes
Company
Deck Type
Sector
Industry
Deck date
January 2022
Slide
28 of 36
Related slides by other companies
Comera
Investor Presentation
December 2023
self administered biologic dosing has multiple potential benefits over infusion for patients potential advantages of over for payers for partners | Comera
Nuvve
Results
May 2023
first mover advantage | Nuvve
Genelux
Investor Presentation
February 2024
a maturing modality with phase companies validating potential gene | Genelux
Absci
Investor Presentation
October 2023
optimization for dual or valent increases potential optimization i | Absci
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io